- Home
- MAV vs LRMR Comparison
MAV vs LRMR Comparison
Compare MAV & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAV
- LRMR
- Stock Information
- Founded
- MAV 2003
- LRMR N/A
- Country
- MAV United States
- LRMR United States
- Employees
- MAV N/A
- LRMR N/A
- Industry
- MAV Finance Companies
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- MAV Finance
- LRMR Health Care
- Exchange
- MAV Nasdaq
- LRMR Nasdaq
- Market Cap
- MAV 193.0M
- LRMR 204.9M
- IPO Year
- MAV N/A
- LRMR N/A
- Fundamental
- Price
- MAV $8.08
- LRMR $4.01
- Analyst Decision
- MAV
- LRMR Strong Buy
- Analyst Count
- MAV 0
- LRMR 8
- Target Price
- MAV N/A
- LRMR $17.88
- AVG Volume (30 Days)
- MAV 66.2K
- LRMR 1.8M
- Earning Date
- MAV 01-01-0001
- LRMR 08-14-2025
- Dividend Yield
- MAV 4.30%
- LRMR N/A
- EPS Growth
- MAV N/A
- LRMR N/A
- EPS
- MAV N/A
- LRMR N/A
- Revenue
- MAV N/A
- LRMR N/A
- Revenue This Year
- MAV N/A
- LRMR N/A
- Revenue Next Year
- MAV N/A
- LRMR N/A
- P/E Ratio
- MAV N/A
- LRMR N/A
- Revenue Growth
- MAV N/A
- LRMR N/A
- 52 Week Low
- MAV $6.37
- LRMR $1.61
- 52 Week High
- MAV $8.34
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- MAV 40.42
- LRMR 60.80
- Support Level
- MAV $8.05
- LRMR $3.42
- Resistance Level
- MAV $8.10
- LRMR $3.97
- Average True Range (ATR)
- MAV 0.03
- LRMR 0.38
- MACD
- MAV 0.00
- LRMR 0.02
- Stochastic Oscillator
- MAV 29.17
- LRMR 67.61
About MAV Pioneer Municipal High Income Advantage Fund Inc.
Pioneer Muni High Income Advantage Tr is a closed-end fund designed to pursue high current income exempt from regular federal income tax, and as a secondary objective, to seek capital appreciation. It predominantly invests in debt securities and other obligations issued by or on behalf of states, territories, and possessions of the United States and the District of Columbia and their political subdivisions, agencies, and instrumentalities, the interest on which is exempt from regular federal income tax.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.